GENB Stock — Generate Biomedicines Inc.: Cash, EV, Pipeline

What they do

Generate Biomedicines, Inc. (the "Company") is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The Company’s vision is to program biology to generate optimal therapeutics for the greatest impact on human health.

Source: 10-Q FY2026 via SEC EDGAR

Share price

$13.06

Market cap

$1,676.3M

Cash

$457.4M

Enterprise value

$1,218.9M

Balance sheet

Cash	$457.4M
Debt	$0.0M
Net cash	$457.4M
Enterprise value	$1,218.9M
Basic shares	128.3M shares
Fully diluted shares	152.6M shares
Fully diluted market cap	$1,993.6M
Cash per share	$3.57
Quarterly burn	$57.9M
Cash runway	7.9 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

128.3M

Pre-funded warrants

0.0M

Options

24.4M

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

152.6M

Cap table as of 2026-06-30.

Price history

Loading GENB daily closes…

Loading price history…

Next catalyst

GB-7624 · Now - Nov 22, 2026 Now · Phase 1 · Atopic Dermatitis (AD)

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Nov 22, 2026 Now	GB-7624	Phase 1	Atopic Dermatitis (AD)	—
Jun 12 - Jul 24 in 7 mo	GB-0895 (SC)	Phase 1	Asthma; COPD (Chronic Obstructive Pulmonary Disease)	—
Jul 13 - Aug 24 in 8 mo	GB-4362	Phase 1	Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma	—
Jan 12 - Feb 23 in 27 mo	GB-0895	Phase 3	Severe Asthma	—
Feb 12 - Mar 26 in 28 mo	GB-0895	Phase 3	Severe Asthma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GB-0895

Phase 3 · Active

Target TSLP

Indications

Severe asthma (Phase 3)

Status note Lead candidate; ongoing Phase 3 clinical trials enrolling globally; company intends to prioritize GB-0895 for severe asthma. No modality or target disclosed in the excerpts. Platform-level collaborations (Novartis, Amgen, MD Anderson, Roswell Park, Flagship/PMCo) are not stated to cover GB-0895.

GB-4362

Stage not disclosed · Active

Target MMAE

Indications

Advanced Urothelial Cancer (Phase 1)
Metastatic Urothelial Carcinoma (Phase 1)

Status note Named as a product candidate in risk factors; no indication, stage, modality, or target disclosed in the excerpts.

GB-5267

Stage not disclosed · Active

Target MUC16

Indications

Platinum-resistant Ovarian Cancer (Phase 1)

Status note Named as a product candidate in risk factors; no indication, stage, modality, or target disclosed in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	GB-0895
Lead indication	Severe Asthma
Lead phase	Phase 3
Active trials	5
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07276724	Phase 3	Recruiting	Sponsor	GENB	—	Severe Asthma	—
NCT07359846	Phase 3	Recruiting	Sponsor	GENB	—	Severe Asthma	—
NCT07116889	Phase 1	Active, not recruiting	Sponsor	GENB	—	Asthma; COPD (Chronic Obstructive Pulmonary Disease)	—
NCT07484022	Phase 1	Recruiting	Sponsor	GENB	—	Advanced Urothelial Cancer; Metastatic Urothelial Carcinoma	—
NCT06920693	Phase 1	Active, not recruiting	Sponsor	GENB	—	Atopic Dermatitis (AD)	—
NCT07489287	Phase 1	Recruiting	Collaborator	Roswell Park Cancer Institute	—	Platinum-resistant Ovarian Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Generate Biomedicines on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	3,283,844	-309,155	2.05%	2026-08-14
Baker Bros. Advisors	1,423,602	no change	0.12%	2026-08-14
Sphera Biotech	245,000	+60,000	0.59%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

GENB — Generate Biomedicines Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

GENB — Generate Biomedicines Inc.